Image of TriNav Infusion Systems

Traditional delivery methods may fall short

Traditional microcatheters can have difficulty overcoming variables that can impede drug delivery, like flow dynamics and intratumoral pressure.4 With SmartValve technology, TriNav Infusion Systems can overcome barriers that can inhibit successful treatment.1-3

Traditional Microcatheter

Image showing T:N Ratio

Therapy distribution with a traditional microcatheter.2

SmartValve Technology

Therapy distribution with SmartValve technology.2

Why use it

Here’s how TriNav is changing the game in therapy delivery:

Precision Icon

Engineered
for Precision

24% increase in the T:N ratio compared to traditional microcatheters (n=61, p<0.001)1

Safety Icon

Designed
for Safety 

Up to 58% mean decrease in non-target embolization and demonstrated reflux protection compared to traditional microcatheters (n=9, p<0.05)2

Outcomes Icon

Focused
on Outcomes

Compared to patients treated with traditional microcatheters, clinical data show patients treated with SmartValve technology experienced:

  • 23% increase in tumor dose (n=61, p=0.001)1
  • 55% increase in pathological response rate (n=23, p=0.026)3
  • 23% increase in objective response rate (n=88, p=0.019)3
  • 61% lower rate of post-procedure in-patient visits (8.0% vs. 20.5%)5,6
  • 5.7% improvement in complication rates5,6
Reimbursement Icon

Advancing Reimbursement and Access

The only device with unique CMS-assigned HCPCS codes for both simulation angiogram (C8004) and treatment (C9797), supporting reimbursement for procedural planning and therapy delivery.

  • $7.7K cost avoidance per case through reductions in in-patient visits and treatment-related complications shown through Real-World Evidence.5,6
Self Centers Image of TriNav
Image of TriNav creating turbulent flow within a vessel
Image of vessel expanding for pressure from TriNav